Cited by 192Ovarian function and disordersReproductive Biology and FertilityReproductive Health and Technologies

Ovarian hyperstimulation syndrome

Open access
Kumar, Pratap, Sait, SameerFarouk, Sharma, Alok, Kumar, Mukesh·2011·Journal of Human Reproductive Sciences

Abstract

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of assisted reproduction technology. The syndrome is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space due to increased capillary permeability and ovarian neoangiogenesis. Its occurrence is dependent on the administration of human chorionic gonadotrophin (hCG). β-hCG and its analogs, estrogen, estradiol, prolactin, histamine and prostaglandins have all been implicated in OHSS but now it is increasingly better understood that the vasoactivesubstances such as interleukins, tumor necrosis factor-α, endothelin-1, and vascular endothelial growth factor (VEGF) secreted by the ovaries have been implicated in increasing vascular permeability. Enlargement of the ovaries causes abdominal pain, nausea and vomiting. Leakage of fluid from follicles, increased capillary permeability leading to third spacing (due to the release of vasoactive substances), or frank rupture of follicles can all cause ascites. Due to leakage of fluid through the impaired blood vessels both within and outside the ovary there is massive fluid-shift from the intra-vescular bed to the third compartment results in intravascular hypovolemia with concomitant development of edema, ascites, hydrothorax and/or hydropericardium. Low-dose gonadotrophin protocols have been implemented to reduce the risks of fertility treatment in polycystic ovary syndrome patients. Prophylactic albumin administration may interrupt the development of OHSS by increasing the plasma oncotic pressure and binding mediators of ovarian origin. OHSS is significantly lower in an antagonist protocol than in an agonist protocol. Cabergoline inhibits partially the VEGF receptor 2 phosphorylation levels and associated vascular permeability without affecting luteal angiogenesis reduces the 'early' (within the first 9 days after hCG) onset of OHSS. To prevent thrombosis, subcutaneous heparin 5000-7500 U/d is begun on the first day of admission. These patients need a hospital ward where the clinical picture is well understood and the personnel have expertise in its treatment and follow-up. Admission to an intensive care unit is necessary when critical OHSS develops.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0974-1208.86080

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PCOS is associated with an increased risk of ovarian hyperstimulation syndrome.

    “PCOS is also associated with an increased risk of ovarian hyperstimulation syndrome, a serious condition resulting from supraphysiologic levels of gonadotropins (Kumar et al., 2011; Tummon et al., 2005)”

    From Endometriosis and polycystic ovary syndrome are diametric disorders (2021) · cites this paper as Kumar et al., 2011

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. [1]Abramov Y Elchalal U Schenker JG Severe OHSS: An ‘epidemic’ of severe OHSS: A price we have to pay? Hum Reprod 1999 14 2181 3 10469676
  2. [2]Golan A Ron-el R Herman A Soffer Y Weinraub Z Caspi E Ovarian hyperstimulation syndrome: An update review Obstet Gynecol Surv 1989 44 430 40 2660037
  3. [3]Morris RS Paulson RJ Ovarian derived prorenin-angiotensin cascade in human reproduction FertilSteril 1994 62 1105 14 7957971
  4. [4]Elchalal U Schenker JG The pathophysiology of ovarian hyperstimulation syndrome-views and ideas Hum Reprod 1997 12 1129 37 9221989
  5. [5]Lee TH Liu CH Huang CC Wu YL Shih YT Ho HN Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Hum Reprod 2008 23 160 7 18000172
  6. [6]Delvigne A Rozenberg S Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review Hum Reprod Update 2002 8 559 77 12498425
  7. [7]Beerendonk CC van Dop PA Braat DD Merkus JM Ovarian hyperstimulation syndrome: Facts and fallacies Obstet Gynecol Surv 1998 53 439 49 9662730
  8. [9]Abramov Y Elchalal U Schenker JG Pulmonary manifestations of severe ovarian hyperstimulation syndrome: A multicenter study Fertil Steril 1999 71 645 51 10202873
  9. [10]Konig E Bussen S Sutterlin M Steck T Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study Hum Reprod 1998 13 2421 4 9806261
  10. [11]McClure N Healy DL Rogers PA Sullivan J Beaton L Haning RV Jr Vascular endothelial growth Review Article 36 factor as capillary permeability agent in ovarian hyperstimulation syndrome Lancet 1994 344 235 6 7913160
  11. [12]Polishuk WZ Schenker JG Ovarian overstimulation syndrome Fertil Steril 1969 20 443 50 5769393
  12. [13]Garcia-Velasco JA Zuniga A Pacheco A Gómez R Simón C Remohí J Coasting acts through down regulation of VEGF gene expression and protein secretion Hum Reprod 2004 19 1530 8 15155606
  13. [14]Nardo LG Cheema P Gelbaya TA Horne G Fitzgerald CT Pease EH The optimal length of ‘coasting protocol’ in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization Hum Fertil (Camb) 2006 9 175 80 17008270
  14. [15]Bellver J Munoz EA Ballesteros A Soares SR Bosch E Simón C Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: A randomized controlled study Hum Reprod 2003 18 2283 8 14585874
  15. [16]Shaker AG Zosmer A Dean N Bekir JS Jacobs HS Tan SL Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome Fertil Steril 1996 65 992 6 8612863
  16. [17]Isik AZ Vicdan K Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome Eur J Obstet Gynecol Reprod Biol 2001 97 208 12 11451550
  17. [18]Forman RG Frydman R Egan D Ross C Barlow DH Severe hyperstimulation syndrome using agonists of gonadotrophin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention FertilSteril 1990 53 502 9 2106456
  18. [19]Al-Inany HG Abou-Setta AM Aboulghar M Gonadotrophin- releasing hormone antagonists for assisted conception Cochrane Database Syst Rev 2006 3 CD001750 16855976
  19. [20]Daya S Gunby J Luteal phase support in assisted reproduction cycles Cochrane Database Syst Rev 2004 3 CD004830 15266541
  20. [21]Sukuikkari AM in-vitro maturation: Its role in fertility treatment Curr Opin Obstet Gynecol 2008 20 242 8 18460938
  21. [22]Adashi EY Resnick CE D’Ercole AJ Svoboda ME VanWyk JJ Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function Endocr Rev 1985 6 400 20 2992919
  22. [23]Barbieri RL Makris A Randall RW Daniels G Kistner RW Ryan KJ Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism J Clin Endocrinol Metab 1986 62 904 10 3514651
  23. [24]Costello MF Chapman M Conway U A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome Hum Reprod 2006 21 1387 99 16449310
  24. [25]Carizza C Abdelmassih V Abdelmassih S Ravizzini P Salgueiro L Salgueiro PT Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study Reprod Biomed Online 2008 17 751 5 19079957
  25. [26]Varnagy A Bodis J Manfai Z Wilhelm F Busznyak C Koppan M Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome Fertil Steril 2010 93 2281 4 19261278
  26. [27]Quintana R Kopcow L Marconi G Young E Yovanovich C Paz DA Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model Fertil Steril 2008 90 4 Suppl 1511 6 18166186
  27. [28]Whelan JG 3rd Vlahos NF The ovarian hyperstimulation syndrome Fertil Steril 2000 73 883 96 10785212
  28. [29]Speroff L Fritz M Clinical Gynecological Endocrinolgy and Infertility 2004 7th ed Philadelphia, Pa Lippincott Williams and Wilkins 1999 200
  29. [30]Navot D Bergh PA Laufer N Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment Fertil Steril 1992 58 249 61 1633889

Cited by

Sorted by citations

Authors
Kumar, P., Sait, S., Sharma, A., & Kumar, M.
Affiliations
  • Manipal Academy of Higher Education (IN)
  • Deen Dayal Upadhyay Hospital (IN)
Corresponding author
Kumar, Pratap
Venue
Journal of Human Reproductive Sciences
Published
2011
Volume
4
Issue
2
Pages
70
ISSN
0974-1208 (ISSN-L)
OpenAlex
W2113378534
Cited by
192
References
0
Citations by year
2026: 11 · 2025: 12 · 2024: 13 · 2023: 20 · 2022: 19 · 2021: 15 · 2020: 21 · 2019: 14 · 2018: 11 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 6 · 2013: 5 · 2012: 4
FWCI
5.38
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Human Reproductive Sciences (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
Keywords
ovarian hyperstimulation syndrome, assisted reproductive technology complications, human chorionic gonadotropin, vascular permeability, ovarian angiogenesis, vasoactive substances, ascites, polycystic ovary syndrome, VEGF receptor 2, cabergoline, GnRH antagonist protocol, heparin prophylaxis, OHSS prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review